Pinnacle Associates’s BridgeBio Pharma BBIO Stock Holding History

Pinnacle Associates’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-14,750	Closed	-$389K	–	820
2023 Q3	$389K	Hold	14,750	–	–	0.01%	603
2023 Q2	$254K	Hold	14,750	–	–	﹤0.01%	724
2023 Q1	$245K	Sell	14,750 -28,750	-66%	-$335K	0.01%	678
2022 Q4	$331K	Sell	43,500 -3,237	-7%	-$31K	0.01%	582
2022 Q3	$465K	Sell	46,737 -5,350	-10%	-$55.6K	0.01%	507
2022 Q2	$473K	Hold	52,087	–	–	0.01%	527
2022 Q1	$529K	Hold	52,087	–	–	0.01%	547
2021 Q4	$869K	Sell	52,087 -200	-0.4%	-$8.46K	0.02%	478
2021 Q3	$2.45M	Hold	52,287	–	–	0.05%	309
2021 Q2	$3.19M	Buy	+52,287	New	+$2.99M	0.06%	276
2020 Q3	–	Sell	-51,044	Closed	-$1.67M	–	680
2020 Q2	$1.67M	Buy	+51,044	New	+$1.55M	0.04%	297
2020 Q1	–	Sell	-5,800	Closed	-$203K	–	663
2019 Q4	$203K	Buy	+5,800	New	+$161K	﹤0.01%	676

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pinnacle Associates's BBIO Position: Q4 2023 in Review

Pinnacle Associates sold out of BridgeBio Pharma (BBIO) in Q4 2023, closing a stake of 14,750 shares — an estimated $389K sold.

Pinnacle Associates first reported a position in BBIO in Q4 2019 and held it in 12 quarters. The position peaked at $3.19M in Q2 2021. 247 funds tracked by Wall St. Rank hold BBIO as of Q4 2023.

Pinnacle Associates reported no remaining BridgeBio Pharma position as of Q4 2023 after selling out during the quarter.
Pinnacle Associates sold 14,750 BridgeBio Pharma shares in Q4 2023, an estimated $389K.
Pinnacle Associates first reported a position in BridgeBio Pharma in Q4 2019 and held it in 12 quarters.
Pinnacle Associates's BridgeBio Pharma position peaked at $3.19M in Q2 2021.
247 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2023.

Based on Pinnacle Associates's 13F filing for Q4 2023, filed 19 Jan 2024.